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Abstract
Since the turn of the millennium, an evolving body of scientific and clinical evidence
indicates that biofilm is implicitly linked to delayed wound healing and infection.
Currently, wound anti-biofilm strategies rely on non-specific wound bed preparation
techniques involving physical debridement and cleansing, and innovative technologies
designed to specifically manage biofilm have only just begun to emerge. The first output
of anti-biofilm research and product development in wound care show great promise for
patients, clinicians and healthcare institutions. The aim of this chapter is to address the
current clinical biofilm problem, describe existing and emerging strategies to combat
wound biofilm and review the available evidence.
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1. Introduction: the clinical problem
Fossil evidence of microorganisms existing as surface-attached microcolonies dates back 3.4
billion years [1], establishing biofilm as one of the oldest life-forms on earth. The scientific study
of surface-attached microorganisms dates back to the seventeenth century [2], but it is only in
recent decades that their relevance has been appreciated in both natural and pathogenic
ecosystems [2, 3]. Although the term ‘biofilm’ has been used to describe surface-attached, matrix-
encased microbial communities in industrial and environmental applications since the 1930s,
it was not until 1985 that Bill Costerton introduced the term into medical microbiology [2]. The
importance of biofilm in chronic infections is now widely accepted and there has been an
exponential rise in related medical publications since 1975, reaching a number of 3251 in 2013
alone [2].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
The refractory nature of many infections has been largely attributed, in recent decades, to the
continuing rise in antibiotic resistance, but the involvement of biofilm in microbial tolerance
to antimicrobial agents and immune cells is increasingly recognised. The combined effect of
biofilm tolerance and antibiotic resistance are the two most important microbial defence
strategies, and in combination present a significant risk to public health. In 1999, Costerton et
al. [4] reported bacterial biofilm as being a common cause of persistent infections that include
conditions such as periodontal disease, otitis media, cystic fibrosis, pneumonia and device
related infections. Although the authors also considered necrotising fasciitis and osteomyeli‐
tis as biofilm infections, wound infections in more general terms were not considered.
Any wound that is not healing and that has not followed a normal wound healing trajectory
is likely to involve biofilm. Healthy skin is an effective microbial barrier; therefore dermal
tissues are intrinsically sterile. However, the surface of the skin is heavily colonised. Damage
to or removal of the epidermal barrier layer will inevitably lead to wound contamination and
opportunistic microbial colonisation. The innate human immune system can usually counter
this invasion but, if the initial contamination event is overwhelming (such as a severe traumatic
wound), or contamination is repetitive (for example for a faecally incontinent subject suffer‐
ing from a sacral pressure ulcer), or if the casualty has a weakened immune system (as a result
of age, disease, malnutrition, obesity, smoking, etc.) then biofilm may become established.
The earliest indirect indication of wound bacteria existing in biofilm form involved the
detection of extracellular polysaccharide capsules surrounding the cells of both aerobic and
anaerobic wound pathogens, using light and scanning electron microscopy [5]. Capsule
production is a key component of a biofilm mode of life that can protect bacterial communi‐
ties from the host immune system [6]. The earliest scientific research into wound biofilm was
reported by Serralta et al. in 2001 [7]. In this in vivo study, both planktonic and biofilm bacterial
lifestyles were observed, with biofilm bacteria (Pseudomonas aeruginosa) exceeding plankton‐
ic bacteria by approximately 100-fold. Whereas the planktonic P. aeruginosa could be re‐
moved by vigorous flushing, adherent biofilm P. aeruginosa could only be removed by forceful
scrubbing with a detergent agent.
The development and evolution of wound biofilm from contamination to a pathogenic state
was proposed in 2004, and the point at which an evolving biofilm begins to interfere with
wound healing and increase the risk of infection has largely replaced the previously-used
term ‘critical colonisation’ [8]. In 2008, a hypothesis (that was considered novel at the time)
relating to why chronic wounds fail to heal was reported [9]. Based on their previous experi‐
ences with chronic P. aeruginosa infections in patients suffering from cystic fibrosis, Bjarn‐
sholt et al. [9] proposed that the inability of polymorphonuclear leukocytes and antibiotic
treatment to eliminate P. aeruginosa biofilm was the cause of recalcitrance in chronic wounds.
Subsequent clinical studies using microscopy and molecular analytical techniques demon‐
strated that biofilm existed in a majority of non-healing chronic wounds [10, 11]. Since 2008,
an increasing number of studies have demonstrated the presence of biofilm in wounds of
varied aetiology [10–21] as indicated in Table 1.
Since the turn of the millennium, wound biofilm has been proposed, investigated and
confirmed, as a factor in chronic wound pathogenesis. From initial evidence of their
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existence [7], role in wound healing [8], and the simultaneous and pioneering confirmation of
their clinical existence in 2008 [10, 11], a large body of scientific and clinical evidence now
suggests that biofilm is inextricably linked to wound infection and delayed healing [7, 22–37]
(Table 2).
Wound types No.Methods Observations Ref.
Chronic (mixed) 50 Light microscopy, scanning
electron microscopy (SEM)
30 chronic wounds observed to
contain biofilm (60%)
10
Chronic (mixed) 22 Confocal laser scanning
microscopy (CLSM)
13 chronic wounds observed to
contain biofilm (59%)
11
Chronic (mixed) 9 Fluorescence microscopy, CLSM P. aeruginosa observed deeper in
wound than S. aureus
12
Chronic (mixed) 10 Fluorescence microscopy, CLSM P. aeruginosa elicited greater inflammation
than S. aureus
13
Chronic 1 Fluorescence microscopy Both samples contained biofilm 9
Mixed aetiologies 15 Fluorescence microscopy 7 wounds observed to contain biofilm (47%) 14
Full-thickness
burns
11 Light & transmission electron
microscopy, SEM
Only ulcerated and escharotomy
sites contained biofilm
15
Diabetic foot ulcers (DFU) 2 CLSM Both samples contained biofilm 16
Acute 16 Light microscopy, SEM 1 acute wound contained biofilm (6%) 10
DFU 4 Light & fluorescence microscopy,
environmental SEM
Microcolonies associated with biofilm
observed in all wounds
17
Surgical sternal 6 Light & fluorescence microscopy,
CLSM, SEM
3D biofilm aggregates observed in all
6 infected wounds
18
Venous leg ulcers (VLU) 45 Transmission electron
microscopy
Biofilm matrices of polysaccharides,
proteins & DNA observed
19
Malignant 32 Fluorescence microscopy Biofilm observed in 35% of wounds 20
Mixed &
non-wound
113 Biofilm-forming capacity of
isolates by culture & SEM
Significantly more biofilm formed by
wound isolates than others
21
Table 1. Key scientific evidence for the presence of biofilm in human wounds.
Model Biofilm species Observations Ref.
Porcine acute S. aureus (S.a) Challenge with antimicrobial agents confirmed the recalcitrance of
biofilm bacteria
7
Porcine acute S.a Polymorphonucleocytes observed on the surface of, but not
within, biofilm
22
Porcine partial
thickness
MRSA, P.
aeruginosa (P.a)
Interactions between MRSA and P.a were observed, delaying
healing due to suppression of epithelialisation and expression of
23
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Model Biofilm species Observations Ref.
virulence factors
Murine burn P.a Microscopic biofilm observed that was not readily removed by rinsing with
saline
24
Murine diabetic
chronic
P.a Biofilm-colonised wounds highly inflamed; 8 weeks for biofilm-colonised
wounds to heal, 4 weeks for controls
25
Murine diabetic
chronic
P.a Biofilm significantly delayed wound healing, even in diabetic mice treated
with insulin
26
Murine infected
surgical
P.a Biofilm highly-tolerant to antibiotics & sodium hypochlorite once
established over several days
27
Murine
chronically-
infected surgical
S.a, P.a, E. faecalis,
F. magna
Polymicrobial biofilm maintained for 12 days, & delayed healing
more than P.a biofilm, by wound closure
28
Murine splinted S.a/S. epidermidis Biofilms significantly delayed epithelialisation; inhibition of biofilm
restored normal healing
29
Rabbit ear S.a Biofilm and active infection significantly delayed healing; biofilm-
colonised wounds expressed significantly lower levels of
inflammatory cytokines than infected wounds
30
Rabbit ear P.a Biofilm significantly delayed healing; debridement, lavage and silver
sulphadiazine in combination were more effective at
restoring healing than individual treatments
31
Rabbit ischaemic
ear
K. pneumonia
(K.p),
S.a, P.a
K.p biofilm was least virulent, P.a biofilm most virulent,
measured by healing inhibition and inflammation; extracellular polymeric
substances (EPS)-deficient P.a
did not delay healing
32
Rabbit ear S.a, P.a 2-species biofilm elicited significantly elevated inflammatory
response & impaired epithelialisation & granulation tissue
formation compared to single-species
33
Rabbit ear P.a Dressing designed specifically to manage biofilm gave significant
reductions in biofilm count & significantly improved wound
healing (granulation & epithelialisation)
34
Murine Natural skin
microflora
Biofilm developed over time in chronic wounds (similar to humans);
reducing oxidative stress increased their susceptibility to
antibiotics & dismantled biofilm
35
Rabbit ear K.p, P.a Wounds showed increased inflammation and delayed healing
with P.a biofilm infection as determined by of wound healing cells
transcriptome analysis
36
Porcine burn P.a, A. baumannii Biofilm-infected wounds, tolerant to silver dressings, eventually closed, but
skin barrier function compromised
37
Diabetic mouse S.a Diabetic wounds had significantly more biofilm & less neutrophil
activity, thus poorer healing than wild type
38
Table 2. Evidence that biofilm delays wound healing from porcine, murine and rabbit ear models.
In our laboratory, we have used microscopy techniques to better understand the structure and
development of wound biofilm. Planktonic cultures of P. aeruginosa were grown on track-
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etched membrane cell culture inserts in culture wells for up to 48 hours, and biofilm growth
was examined at various stages of development by light microscopy (LM), scanning electron
microscopy (SEM) and transmission electron microscopy (TEM). Biofilm was shown to form
within 6 hours, and becoming established after 24–48 hours (Figure 1). This favourably
compares with previous work reported [39] in which mature P. aeruginosa biofilm formed
within 5 hours of initial inoculation. Stages of biofilm observed in vitro may correlate with our
understanding of wound biofilm development and its link to chronicity and infection
(Figure 1).
Figure 1. Evolution of P. aeruginosa biofilm over 48 hours, with evidence of microcolony formation, maturation and
dispersal.
Numerous in vivo models have been reported in recent years, and these have been critically
reviewed and compared [40]. The rabbit ear model developed by Tom Mustoe’s team in
Illinois, USA is perhaps the most developed and validated of the models [30], has demon‐
strated clear links between wound biofilm and healing, and has also been used to compare the
effectiveness of anti-biofilm strategies [31, 34, 41–43].
Scientific, clinical and animal evidence strongly suggests that biofilm delays wound healing
[44], and efforts are underway to understand and develop ways to visualise and control biofilm
to aid clinical practice [44, 46]. It has been shown that by targeting and suppressing biofilm
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healing can be improved, so the onus is now on wound care product developers and manu‐
facturers to offer technologies with anti-biofilm effectiveness.
2. Therapeutic anti-biofilm strategies
With only relatively recent recognition of the existence of biofilm in wounds and consequent
role it plays in delayed healing and chronicity [8, 10, 11], the development of effective
therapeutic treatments and strategies to date has been very limited. However, this late
recognition does mean that wound care researchers can benefit from the knowledge gained in
other industries and in related healthcare areas such as dentistry and indwelling medical
devices. Here treatment strategy options are well developed and broadly similar. Although
the intention to prevent, remove and kill bacterial biofilm is the same, there is a significant
challenge in selecting wound treatments that have an appropriate balance of safety versus
efficacy. There are also challenges in simultaneously addressing the other clinical needs of the
wound as, unlike inert medical devices or tooth enamel, the surface of a wound, particularly
a chronic wound, can be acutely sensitive and fragile.
Wound biofilm is generally initially attached to the wound bed which is a dynamic mixture
of viable and non-viable (slough) tissues. Exudate permeates through this underlying tissue
Figure 2. Anti-biofilm strategies for wound care—prevention, removal, killing.
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providing moisture and nutrients to developing biofilm. Treatment and prevention of wound
infection usually consists of systemic antibiotics and/or topical antiseptics. The polymicrobi‐
al nature of wound bioburden [5] and difficulty in identification of species present means that
antibiotic selection and coverage is imperfect. Chronic wounds are often poorly perfused with
blood (a causative factor) therefore delivery of systemic antibiotics, at a sustained therapeu‐
tic concentration, for the period necessary to diffuse into a biofilm and take effect, is an
additional challenge [47]. Topical antiseptics are preferred because of their broad spectrum of
activity, but they suffer from a lack of selectivity towards bacteria and therefore can be toxic
to host tissues. General reaction with organic matter and continual dilution and removal with
wound exudate mean that an antimicrobial product needs to be continuously instilled [48] or
formulated for slow release and physical retention within the wound or dosed at high
concentration. Clinical evidence suggests that none of the above existing systemic or topical
treatments are particularly effective against wound biofilm. Therefore, different strategies are
required.
It is convenient to consider these strategies in broad groups aligned with the clinical intent as
mentioned above—to prevent, to remove, to kill biofilm-associated organisms (Figure 2)—and
many treatments will involve combinations of these with the best being a combination of all
three. We will also discuss the anti-biofilm effectiveness of existing methods together with
associated devices, and how some of these are providing therapeutic advances in the emerg‐
ing ‘biofilm era’ of wound care.
2.1. Prevention of biofilm
Microbial contamination of breaches in skin integrity is inevitable, unless the wound is created
under aseptic surgical conditions, and wounds that are not successfully managed can become
chronic and at risk of infection. The ideal situation is to prevent bacteria entering the wound
in the first instance. The risk of wound contamination post-surgery can be addressed by
applying effective microbial barrier dressings. In the 1990s DuoDERM® hydrocolloid adhe‐
sive dressings were shown to reduce the rate of infection (compared to traditional gauze
dressings) [49] and these dressings were later shown to provide a physical barrier to both
bacteria and viruses [50]. More recently, combined physical and antimicrobial barrier
dressings have been developed to minimise the risk of post-operative infection [51].
Although barrier dressings have an important role to play in minimising infection, it is most
likely that any open wound will become contaminated to some extent (chronic wounds will
become significantly more contaminated than most surgical wounds). Consequently, an
important infection control strategy at this point is to prevent microbial attachment to the
wound tissue. This might be achieved by chemical or biological treatment of the wound
surface. Examples of the former are lactoferrin and xylitol. Lactoferrin [52, 53] is a protein that
is believed to inhibit the effectiveness of bacterial adhesins by its ability to sequester iron from
acidic environments, particularly for Gram-negative bacteria [54]. It has proven useful in the
preservation of meat but in a living system with a functioning circulating system supplying
an excess of iron and buffering to neutral pH there will be challenges in maintaining efficacy.
If derived from non-human sources there is also the possibility that lactoferrin may be
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identified by the immune system as a threat and illicit an inflammatory response. Xylitol is a
naturally occurring sugar that binds to the surface of Gram-positive bacteria preventing
adhesion [53], inhibiting glycocalyces (exopolymeric substances) and disrupting cell wall
growth [54]. But xylitol faces the same challenge as lactoferrin in that it is a freely soluble
substance and will be difficult to maintain at an effective concentration in an exuding wound.
Gallium is also mooted in this space as Ga3+ is similar to Fe3+ in size but does not undergo the
same redox reactions (Fe3+ ↔  Fe2+) and therefore interferes with bacterial attachment and
proliferation [52].
If microorganisms gain the opportunity to attach to wound tissue and acclimatise to the
environment, then subsequent colonisation will lead to the development and maturation of a
predominantly biofilm population that is protected from the immediate hostilities within the
wound environment (Figure 1). Two potential biological approaches for controlling biofilm
development are quorum sensing (QS) inhibitors and probiotics. Quorum sensing is an active
field of research with over 100 bacterial species identified as having the ability to communi‐
cate by release of small signalling molecules [55]. At a critical concentration, microbial
communication between cells triggers a change in gene expression which results in a change
in behaviour. QS is involved at all stages in the biofilm life cycle (initial attachment, EPS
expression, proliferation, maturation and dispersal) and is implicated in biofilm virulence. In
practical terms, this minimum concentration dependence translates into a minimum thresh‐
old bacterial population density. However, it must be borne in mind that wound biofilms are
polymicrobial [56–58] and although approximately 50% of all known QS bacterial species have
the ‘universal’ autoinducer 2 (AI-2) [55], QS signal molecules vary between species and strains.
Therefore, a universal inhibitor for wound biofilm formation seems unlikely in the near future.
Probiotics [59, 60] offer the interesting possibility of prophylactically colonising the wound
with non-pathogenic bacteria. Lactobacillus species have been shown to successfully out-
compete and inhibit the pathogenic activity of P. aeruginosa and S. aureus possibly through QS
inhibiting effects [59]. However, there are significant challenges, particularly for chronic
wounds, in how to selectively provide conditions for the survival and growth of probiotic
microorganisms in an already contaminated and inflammatory wound.
Finally, often overlooked is the management of the wound environment itself—establishing
the best conditions in which the body’s immune system can function and/or creating condi‐
tions which reduce bacterial proliferation and biofilm development. The optimal moisture
balance in the wound bed is reported to be 100% humidity with no free liquid [61], and it has
recently been suggested that poor exudate control is likely to encourage the development of
biofilm [62]. Chronic, non-healing wounds are often characterised by a high pH (7.15–8.9) and
healing wounds tend to have a lower pH [63]. The increased production of S. aureus EPS with
increasing pH has been reported [64], but other examples describe the opposite, so the
relationship between biofilm and pH appears to be complex [65, 66].
2.2. Removal of biofilm
By the time wounds are presented to a wound care specialist, the majority of non-healing
traumatic and chronic wounds are likely to be biofilm impeded. There is a long history of
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removing non-viable and necrotic host tissue from wounds (debridement) in order to
encourage the inflammatory, granulation and epithelialisation processes of wound closure.
Surgical debridement techniques can range from aggressive surgical or sharp removal of tissue
to less invasive techniques such as curettage and lavage. This practice is likely to have
coincidentally been removing biofilm with beneficial effect. With increasing familiarity with
the appearance of biofilm or more likely, the symptomatic signs of its presence, clinicians are
seeking methods to physically remove biofilm from wounds. In recent years, debridement
devices utilising a number of very different technologies have emerged.
Sharp debridement is the most radical approach and requires expertise [67]. Excision of
devitalised host tissue (i.e. necrosis) or infected/biofilm tissue via scalpel or other surgical
instrument until the exposed tissue is bleeding would certainly be expected to remove a
majority of any biofilm residing in the wound, but the deleterious effects on healing tissues
need to be balanced with the need to remove unhealthy tissue. However, sharp debridement
has proven successful and advocates such as Wolcott have developed protocols where regular
sharp debridement has provided a ‘healing window’ during which improved effectiveness of
concurrent antimicrobial treatment has been observed [68]. Hurlow has also reported the
atraumatic removal of biofilm above a non-healing surgical wound with exposed tendon using
curettage and antimicrobial cleansers [69, 70] (Table 3).
A number of other devices that can be used for wound debridement are now commercially
available. Examples include devices that emit energy in the form of water jets (lavage),
ultrasound and cold plasma (Table 3). High pressure lavage using hand-held devices [67] has
been assessed in several laboratory and clinical investigations, and there is evidence that
removal of unwanted tissue (which may include biofilm) using this method encourages wound
progression [71]. Ultrasonic wound debridement has proven effective in clinical cases [72], and
scientific studies support the ability of ultrasound to disrupt biofilm and encourage healing in
vivo [42], as well as potentiate the effects of antiseptics via its anti-biofilm action in vitro [73].
Finally, encouraging in vitro anti-biofilm effectiveness of cold atmospheric pressure plasma
technology suggests that the reactive oxygen species produced in precise beams by these
devices may disrupt and kill biofilm while sparing host tissues [74].
Unfortunately, in many clinical institutions the skills, training and equipment for the use of
advanced debridement techniques or devices may not be available. Under these circumstan‐
ces simple cleansing, enhanced with ‘soft debridement’ using engineered textiles, may be
helpful. Recently, debridement pads or wipes have emerged which aim to gently brush and
lift away wound debris. A polyester filament pad has generated encouraging clinical effec‐
tiveness data [75, 76] and cost-saving estimates [77]. In addition to disrupting and lifting
surface-associated wound debris (which is likely to include biofilm), these soft debridement
devices are simple and safe to use, gentle on patients and relatively low-cost, compared to
most other debridement techniques and devices discussed in Table 3.
More thorough biofilm removal may be achieved by degrading the structure of the EPS such
that it flows away from the wound or can be more readily irrigated or absorbed by absorb‐
ent dressings. General proteolytic enzymes have been used for many decades to remove slough
and necrotic tissue, but, as EPS is not primarily comprised of extracellular proteins for its
Wound Biofilm and Therapeutic Strategies
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structural integrity, these are ineffective. This fact has been utilised by an aid to detect the
presence of wound biofilm [45]. Alternative enzymatic candidates that are effective against
polysaccharides have been identified and reviewed [78, 79], and include: α-amylase (mam‐
malian), polysaccharide depolymerase (bacteriophage), alginate lyase (bacterial) and glyco‐
side hydrolase (DspB) (bacterial). Generally, the kinetics of enzyme reactions are known to be
sensitive to pH, for example Dispersin B, despite demonstrating some activity in vitro [80], has
optimal activity at pH 5, and as proteins, enzymes will be vulnerable to the high concentra‐
tions of proteolytic enzymes often associated with chronic wounds. Hence, careful formula‐
tion of any enzyme based anti-biofilm treatment would be required. Sun et al. also point out
that the current high cost of industrial enzyme production makes the application of these
enzymes relatively expensive [79].
Debridement
method
Evidence for effectiveness
against biofilm
Ref.
Curettage (Clinical) Gentle scraping of suspected biofilm (in combination with other antimicrobials)
improved healing in case studies
69,70
Lavage/water jets (Clinical) Indirect anti-biofilm evidence; debridement with Versajet II (Smith & Nephew)
removed unwanted tissue & encourages healing
71
Ultrasound (In vitro) Anti-biofilm action demonstrated in agar biofilm model using Ultrasonic-Assisted
Wound (UAW) device (Soring)
73
(In vivo) Leporine ear model showed MIST (Celleration) reduced P. aeruginosa biofilm &
inflammation, & improved healing parameters
42
(Clinical) Indirect anti-biofilm evidence; case study evidence that UAW can effectively
debride unwanted tissue
72
Cold plasma (In vitro) Biofilm significantly reduced using Coblation (Smith & Nephew) compared to
lavage or curettage in porcine explant model
74
Soft debridement
pads
(Clinical) Indirect anti-biofilm evidence in case studies where sloughy wounds were well
managed using Debrisoft (Lohmann & Rauscher)
75
(Clinical) Debridement was classed as effective in 94% of patients, removing debris and
slough, in a 57-patient study using Debrisoft
76
Table 3. Biofilm removal using debridement methods and devices.
Structural degradation of biofilm EPS can also be achieved chemically. Divalent cations such
as calcium and magnesium are known to be involved in cross-linking polysaccharides within
EPS and manganese and iron are involved in bacterial metabolism and cell wall structure [81].
Competition for these ions or their removal (chelation) will therefore affect biofilm forma‐
tion and strength. Metal chelating agents are a diverse set of compounds but biocompatibili‐
ty and safety considerations restrict those that can be considered for wound care to
ethylenediamine tetra acetic acid (EDTA) and its homologues and polyanionic compounds
such as phosphates and citrate. The most widely discussed of these as an anti-biofilm agent
and the one with the greatest affinity for calcium and magnesium cations is EDTA. The
literature primarily focuses on the tetra-sodium salt form but only at high pH (>pH 10) [81],
which is incompatible with wound management practices. Lower pH forms of EDTA, such as
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the di-sodium salt, are effective but all anionic chelating agents are pH-sensitive. A water-
soluble gel formulation that contains 0.1% EDTA, acetic acid, citric acid and carbopol has
demonstrated anti-biofilm effectiveness against P. aeruginosa and S. epidermidis in vitro [82].
Empirical experience in other industries such as food, laundry, personal washing and dental
products [83] has shown the utility of surfactants as anti-biofilm agents to facilitate penetra‐
tion of combination agents through biofilm EPS [84], leading to detachment from surfaces and
prevention from re-deposition by micelle formation. An anti-biofilm gel comprising a
surfactant and calcium chelator has shown in vitro and in vivo anti-biofilm activity. Although
not yet commercially available, use of this gel has shown clinical superiority to standard
wound care, as well as apparent synergy with standard care [85].
2.3. Killing of biofilm microorganisms
The efficacy of existing antimicrobial therapies in wound care has almost exclusively been
based on their activity against susceptible planktonic bacteria. Whilst associated devices may
be useful in controlling this bacterial phenotype by reducing the risk of contamination and
dispersal, their effectiveness against biofilm is unproven. Indeed, the prevalence and recur‐
rence of chronic wounds suggests that most antimicrobial therapies are ineffective.
Considering the selective and specific action of antibiotics, the polymicrobial nature of wound
bioburden and the increasing threat of multi-drug resistant organisms (MDROs), the effec‐
tiveness of antibiotics in chronic wound care is questionable. However, utilising state of the
art molecular microbiological techniques, personalised cocktails of topically-applied antibiot‐
ics yielded better results than patients receiving systemic antibiotics prescribed using the same
diagnostic techniques who, in turn, yielded better outcomes than a standard-of-care group
treated upon data from standard culture techniques [86]. Unfortunately, this level of diagnos‐
tic sophistication is not within the reach of most health care systems, and therefore we must
await further technological advancements so that it becomes generally affordable.
The majority of wound treatments do not have the benefit of sophisticated microbiological
analysis; therefore any antimicrobial therapy administered must have broad-spectrum
activity. Choice then becomes restricted to antiseptics which can only be applied topically.
Antiseptics are chemically reactive species that are largely non-selective in their action,
therefore potential cytotoxicity (local toxicity to skin cells) and systemic toxicity must be taken
into account. Toxicity is generally managed by limiting the concentration and time of exposure
to the antimicrobial agent. Therefore, antimicrobial cleansing at dressing change may involve
slightly higher concentrations of antiseptic than an antimicrobial dressing which may stay in
situ for several days. However, given that the minimum biofilm eradication concentration
(MBEC) for antiseptics in wound relevant bacteria is often between 10–1000 times greater than
its minimum inhibitory concentration (MIC) for planktonic bacteria (the value upon which
most products are formulated) [87], the balance of safety versus efficacy of antiseptic agents
is challenging. Topical wound antiseptic treatments typically involve 0.5 to 12% for silver in
dressings (depending on the form of silver), approximately 1% for molecular iodine in
dressings (or 10% as povidone iodine), 2 to 4% for chlorhexidine gluconate in cleansers and
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0.1% for polyhexamethylene biguanide (PHMB) in cleansers. Increasing the concentration of
the antiseptic component to be effective against biofilm may not be possible, practical or safe.
Clinical experience and safety reviews have limited the number of usable antiseptic substan‐
ces. Currently, silver is the most widely-used topical antiseptic agent, primarily due to its good
safety versus efficacy balance [88]. Silver is the most studied topical antiseptic [52, 53], and
ionic silver—the antimicrobial active form—has a particularly high affinity for sulphur atoms,
binding irreversibly to thiol groups. Ionic silver also binds to nitrogen atoms in amines and
oxygen atoms in carboxylates, although less strongly. These three interactions lead to very
efficient denaturing of peptides, proteins and enzymes—all of which are essential to bacteri‐
al structure and metabolism. However, carboxylate functional groups are also found within
the polysaccharide in EPS. Therefore, although ionic silver may be inactivated by EPS and
other organic matter within the biofilm, there is a theoretical basis for it to have some biofilm
disruptive effects. Evidence for this effect was a reduction in EPS mechanical strength of an S.
epidermidis biofilm after the application of dilute silver ion solution [89] (Table 4). Similar
observations have been made for a silver-containing carboxymethylcellulose dressing [90, 91],
and it was reported wound dressings with hydrophobic base material impregnated with silver
had sustained anti-biofilm activity [92] (Table 4).
Molecular iodine has proven too toxic for direct application but, by complexation with a carrier
molecule and careful formulation, acceptable slow release products have been developed.
Although the mode of action of molecular iodine is not fully understood [52], studies sug‐
gest that in common with silver, sulphur atoms are a reaction target resulting in protein
denaturing and subsequent changes to cell wall structure [93]. Iodine will react with unsatu‐
rated fats and lipids and organic matter within the wound, and is known to be trapped by
polysaccharides. There is limited evidence that molecular iodine has anti-biofilm properties,
aside from in simple in vitro models [94], but ex vivo studies of a formulated cadexomer iodine
product suggest that sustained release may result in biofilm penetration [95] (Table 4).
Evidence for the anti-biofilm effects of the cationic, nitrogen containing, surfactant-like
antibacterials—chlorhexidine (CHG), PHMB and octenidine—in wound care is limited. CHG
has been shown to have limited effect against some biofilms in vitro but to be ineffective against
others, and the theoretical electrostatic effect on bacterial cell walls as the antimicrobial
mechanism is believed to be negated by biofilm, so the observed effects are unexplained [96].
PHMB is similar in structure to CHG and is proposed to accumulate within biofilm by
electrostatic interactions [97], i.e. cationic PHMB binds to the anionic polysaccharide of EPS
[98]—initially, at least, this will have an inactivating effect on the antimicrobial action.
Available anti-biofilm data focus on formulated products [99–104], so laboratory and clinical
results cannot be attributed solely to PHMB (Table 4). Octenidine has been tested in vitro
against S. aureus biofilm, and above a critical concentration bioburden reduction rate was seen
to increase, but biofilm was possibly removed to surfactancy rather than specific anti-bio‐
film activity [105].
The next most popular traditional antiseptic substances are the molecular halogens and related
oxidising compounds. Chlorine itself is too toxic to be used and hypochlorite-based bleaches
are considered too cytotoxic for general wound care. Hypochlorous acid (HOCl) and chlor‐
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ine dioxide (ClO2) are under consideration [52] as potent, fast-acting cleansing solutions, and
some early anti-biofilm effectiveness has been observed in vitro or inferred clinically for various
HOCl formulations [104, 106–108] (Table 4).
Antimicrobial agent Evidence for effectiveness of formulated product against biofilm Ref.
Ionic silver (In vitro) Reduction in S. epidermidis biofilm
EPS mechanical strength after application of dilute (50 ppb [ng/ml])
silver solution
89
(In vitro) Anti-biofilm activity of silver Hydrofiber
(AQUACEL Ag; ConvaTec) shown over 48 hours using
range of biofilm models
90,91
(In vitro) Sustained anti-biofilm activity evident for at
least 7 days, independent of the microbial strain
92
Molecular iodine (In vitro) Povidone iodine dressing (Inadine; Systagenix)
demonstrated greater anti-biofilm activity than silver dressings
94
(In vitro) Cadexomer iodine dressing (Iodoflex; Smith & Nephew)
demonstrated anti-biofilm activity in P. aeruginosa ex vivo model
95
PHMB with
alkylamidopropyl betaine
solution /gel
(In vitro) Biofilm matrix on human dermal cell line was disrupted,
releasing bacteria for killing, by Prontosan (B. Braun)
104
(In vivo) Anti-biofilm effectiveness of Prontosan was
significantly more effective than inactive controls in porcine dermal wounds
100
(Clinical) Signs of biofilm & infection reduced, healing
progression observed in 124-patient study using Prontosan gel
101
Hypochlorous acid (In vitro) 0.01% HOCl killing of CDC reactor-grown P. aeruginosa
biofilm by live-dead staining with confocal microscopy
106
(In vitro) Biofilm matrix on human dermal cell line was
disrupted, releasing bacteria for killing, using a concentrated HOCl solution
104
(Clinical) Signs of infection reduced & progress toward
healing in a 31-patient study using Vashe (PuriCore)
107
(Clinical) Infection contolled & wounds healed in
14 osteomyelitis patients using Dermacyn (Oculus)
108
Table 4. Examples of existing topical antimicrobial products with some anti-biofilm activity.
2.4. State of the art today
2.4.1. Multi-modal strategies
Perhaps the most straightforward way for wound care clinicians to implement more effec‐
tive biofilm management strategies today is to consider how dental care has embraced multiple
strategies to manage dental plaque biofilm. By using combinations of debridement (brush‐
ing, flossing), surfactants with antimicrobials (toothpaste), and antimicrobial rinses (mouth‐
wash), most consumers manage biofilm effectively on a daily basis to maintain oral hygiene,
and prevent conditions such as dental caries and periodontitis.
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Biofilm-based wound care (BBWC) is an emerging and evidently effective way of combining
multiple modes of wound treatment to improve the health of chronic and infected wounds [68,
85, 109]. Practised initially by the pioneering wound care physician, Randall Wolcott in Texas,
a first assumption of BBWC is made that most (if not all) chronic or infected wounds contain
biofilm. A further assumption is that one mode of treatment may not suffice, therefore the use
of combinations of vigorous debridement, cleansers or gels, topical antimicrobial or anti-
biofilm agents, and wound dressings, is required. Wolcott et al. [85, 109–111] have shown how
BBWC can result in significantly improved outcomes compared to standard wound care in
several large patient cohorts. A number of case studies reported by Hurlow and Bowler [69,
70] have also described how protocols of care designed to target biofilm result in improved
wound outcomes. Combining lactoferrin and xylitol (see Section 2.1) in a hydrogel in con‐
junction with a silver wound dressing demonstrated good efficacy against biofilms [53].
We also firmly believe that the multi-modal approach is the most effective way of rapidly
improving wound health in chronic wounds that are likely compromised by biofilm or
infection. A key component in such protocols of care is undoubtedly efficacious wound
dressings which can provide effective, sustained and safe antimicrobial and anti-biofilm
action. Although the focus here is on therapeutic approaches towards wound biofilm, biofilm
cannot be considered in isolation. Other challenging wound conditions must be considered
alongside biofilm—exudate must be managed, infection must be controlled, the wound must
be protected, and pain must be considered—to provide outcomes that can improve quality of
life.
Most established antimicrobial dressings are very efficient at managing planktonic bacteria,
thereby limiting initial contamination and spread of infection. However, they all suffer the
same challenge in the treatment of biofilm in that the antimicrobial agent must penetrate the
EPS in order to reach the target bacteria and, when they do so, they largely rely on metabo‐
lism to draw them into the bacterial cell for them to act. EPS can restrict the movement of
antimicrobial agents by binding them and increasing the likelihood of reaction with other
organic matter. If the agent is able to reach the target bacterial cell it must do so in a concen‐
tration sufficient to be cidal for the sessile (biofilm) phenotype. Therefore, it is clear that
universally successful antimicrobial therapy using a topical antiseptic agent can only be
achieved by a sustained application or release in combination with some form of EPS (biofilm)
disruption.
2.4.2. An anti-biofilm wound dressing
In 2009, the authors of this chapter undertook a substantial research project to design a wound
dressing specifically to manage biofilm. The starting point was taken as an existing antimi‐
crobial dressing, AQUACEL® Ag. This dressing has a well-documented clinical history for
patient acceptance, safety, management of exudate and reducing the risk of infection [112–
115]. In vitro studies have demonstrated this product to be effective against a broad spec‐
trum of pathogenic bacteria in their planktonic form, including pathogenic multi-drug-
resistant species and clinical wound isolates that have shown high levels of antiseptic tolerance
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in vivo [116–121]. In addition, this dressing has shown some in vitro anti-biofilm activity in
simple models [90, 91]. Using the MBEC method [122] the ability of combinations of anti-
biofilm agents, surfactants and ionic silver to eliminate mature P. aeruginosa biofilm after 30
minutes contact was investigated. Component concentrations were varied, as was pH, and in
all over 60000 tests were performed. Very few combinations proved to be beneficial, but a
number of strong synergistic effects were identified, in particular between ionic silver,
quaternary ammonium surfactants and metal-chelating agents (especially EDTA), all at a
slightly acidic pH [123]. These synergistic components (termed Ag+ Technology) were incor‐
porated into the dressing and subjected to extensive safety testing. We believe that the resultant
dressing, AQUACEL® Ag+ Extra™, is the first commercially available wound dressing
specifically designed to manage biofilm.
In the laboratory AQUACEL Ag+ Extra dressings have demonstrated effectiveness against
biofilm microorganisms in sophisticated in vitro wound models. Here, thick biofilms of multi-
drug-resistant S. aureus or P. aeruginosa were grown on cotton gauze substrates, and placed on
to a simulated wound bed of nutrient agar, within model peri-wound skin [124] (Table 5).
Further studies using isothermal microcalorimetry demonstrated how neither the standard
silver dressing alone (AQUACEL Ag) nor silver nitrate solution showed a marked anti-biofilm
activity, while the AQUACEL Ag+ Extra dressing eradicated the S. aureus biofilm in vitro [125].
Interestingly, in this study the anti-biofilm agents alone, without silver, were also shown to be
ineffective unless combined with silver, demonstrating the synergistic nature of this anti-
biofilm formulation (Table 5).
The efficacy of this combination of ionic silver, metal chelator and surfactant has also been
demonstrated in an FDA-recognised in vivo model of wound healing [30]. Here, the control‐
led formation of P. aeruginosa biofilm and polymicrobial biofilm (P. aeruginosa and S. aureus)
in an acute wound of defined size, and its subsequent treatment, was assessed over time by
measuring parameters such as viable biofilm counts, granulation tissue formation and
epithelialisation. The anti-biofilm dressing was found to be significantly superior to a PHMB-
containing dressing in improving these wound parameters [34] (Table 5).
Most encouraging is the early clinical performance data emerging for this new anti-biofilm
technology. Harding et al. [126] demonstrated the safety and effectiveness of this dressing
containing Ag+ Technology in a 42-patient study in VLU patients. In particular, the authors
highlighted a subset of 10 clinically-infected wounds (where biofilm was assumed to be a
problem) that responded in a more dramatic fashion (Table 5). European and Canadian clinical
evaluations summarised 113 cases which were selected on the basis of being difficult-to-heal
wounds, with suspected involvement of infection or biofilm. Following an average of 4.1 weeks
of use of the new dressing in otherwise standard wound care protocols, an average wound
closure of 73% was achieved, with 17% of wounds healing completely [127] (Table 5). More
detailed individual case studies from these evaluations have also been presented [128]. In more
recent UK-based evaluations of AQUACEL Ag+ EXTRA, a 29-case evaluation reported
reductions in all described signs of clinical infection, including a reduction in suspected biofilm
from 76 to 45%. This was accompanied by an average wound closure of 62%, with 34% of
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wounds fully healing after an average of 5.4 weeks of dressing use [129] (Table 5). Finally, a
112-patient post-market surveillance study further demonstrated the safety and effective‐
ness of this dressing, shifting stagnant or deteriorating wounds, that had previously been
managed with a large variety of standard antimicrobial products, onto healing trajectories
[130] (Table 5).
Study type Summary of results Ref.
In vitro Assessed quantitatively by viable counts & confocal scanning laser microscopy, AQUACEL Ag+
Extra gave 6 log10 kill of P. aeruginosa and CA-MRSA biofilm after 4 & 5 days; standard AQUACEL
Ag dressing did not fully eradicate either biofilm
124
Dressing & silver nitrate+EDTA+BC eradicated S. aureus biofilm; silver CMC dressing, CMC
dressing, EDTA+BC, & silver nitrate alone did not eradicate biofilm; demonstrating synergy of
silver with metal chelator & surfactant
125
In vivo The new dressing technology gave 2 log10 reductions in P. aeruginosa or polymicrobial biofilm after
4 & 6 days compared to PHMB gauze & CMC dressings; granulation tissue formation &
epithelialisation significantly better after new dressing
34
Clinical study An acceptable safety profile was demonstrated; after 4 weeks of the new dressing then 4 weeks
CMC 12% of wounds healed, 76% showed improvement; mean ulcer size reduction 55%; subset of
10 infected wounds reduced in area by 70%
126
Clinical
evaluation
The new dressing resulted in an average wound closure of 73% after average of 4.1 weeks of use in
113 cases; 17% of wounds healed completely
127
62% average wound closure after 5.4 weeks of AQUACEL Ag+ Extra dressing use; 34% of wounds
healed completely; exudate & signs of suspected biofilm & infection reduced in 29-case evaluation
129
Safety & effectiveness demonstrated in 112-case evaluation; suspected biofilm coverage of wound
reduced; 13 of wounds healed completely, 65% improved after 3.9 weeks of AQUACEL Ag+ Extra
dressing use
130
Table 5. Evidence for a dressing designed specifically to manage exudate, infection and biofilm.
3. Conclusions and future perspectives
Biofilm is increasingly accepted as an integral component of wound recalcitrance and infection,
and is likely a key reason for the frequent failure of antibiotics and antiseptics in wound
healing. Strategies for combating wound biofilm are currently limited and non-specific
physical debridement techniques—from physical removal with absorbent dressings, pads and
wipes, to sharp and surgical tissue removal—remain the most effective approach. Despite the
limited available anti-biofilm wound strategies, efforts are in progress to develop durable
medical devices and wound dressings that combine anti-biofilm and antimicrobial activity.
To-date and to our knowledge, only one dressing has been designed to combat biofilm
(Figure 3), and there is a growing body of evidence demonstrating the exceptional clinical
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effectiveness of this dressing (AQUACEL Ag+ Extra) [126–130]. It is likely that future efforts
will continue to investigate combination technologies that will disrupt biofilm to enhance the
antimicrobial efficacy of antiseptics and antibiotics. Certainly, eradication of wound biofilm is
critical to promotion of healing and hence improving the lives of patients debilitated by wound
recalcitrance.
Figure 3. The ideal anti-biofilm wound dressing—prevention, removal, killing.
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